Table 1.
Individuals diagnosed with conduct disorder | ||
n=71 419 | Percentage | |
Male (vs female) | 46 082 | 64.5% |
Racial and ethnic characteristics | ||
Non-Hispanic white | 41 248 | 57.8% |
Non-Hispanic black | 15 303 | 21.4% |
Hispanic | 6965 | 9.8% |
Unknown ethnicity | 12 978 | 18.2% |
Unknown race | 9993 | 14.0% |
Asian | 1049 | 1.5% |
Other race | 2994 | 4.2% |
Native Hawaiian or Pacific Islander | 438 | 0.6% |
Native American | 394 | 0.6% |
Age at time of index (first) diagnosis, in years (SD) | 14.7 | 2.7 |
Psychiatric diagnoses | ||
Attention-deficit hyperactivity disorder | 41 608 | 58.3% |
Generalised anxiety disorder | 7341 | 10.3% |
Post-traumatic stress disorder | 6981 | 9.8% |
Adjustment disorder | 7957 | 11.1% |
Obsessive-compulsive disorder | 2682 | 3.8% |
Mood (affective) disorders (major depressive or bipolar disorder) | 33 246 | 46.6% |
Schizophrenia-spectrum disorders | 3074 | 4.3% |
Personality disorders | 3334 | 4.7% |
Impulse control disorders | 4998 | 7.0% |
Autism spectrum disorders | 8943 | 12.5% |
Intellectual disabilities | 5846 | 8.2% |
Any substance use disorder (alcohol, stimulant, cannabis, sedative) | 9963 | 14.0% |
Cannabis use disorder | 6356 | 8.9% |
Psychotropic medications | ||
Antipsychotics | 21 359 | 29.9% |
Risperidone | 8088 | 11.3% |
Aripiprazole | 7551 | 10.6% |
Quetiapine | 4191 | 5.9% |
Olanzapine | 3760 | 5.3% |
Haloperidol | 3543 | 5.0% |
Ziprasidone | 1579 | 2.2% |
Lurasidone | 666 | 0.9% |
Psychostimulants | 23 256 | 32.6% |
Amphetamine stimulants | 12 046 | 16.9% |
Amphetamine Salts | 7633 | 10.7% |
Dextroamphetamine | 7861 | 11.0% |
Methylphenidate | 12 220 | 17.1% |
Dexmethylphenidate | 3651 | 5.1% |
Lisdexamfetamine | 5738 | 8.0% |
Antidepressants and mood stabilisers | ||
Any selective serotonin reuptake inhibitors | 20 468 | 28.7% |
Lithium | 613 | 0.9% |
Lamotrigine | 2640 | 3.7% |
Carbamazepine | 529 | 0.7% |
Valproate | 3592 | 5.0% |